Dr. Donna A. Culton, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of North Carolina at Chapel Hill School of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 372
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: University of North Carolina at Chapel Hill School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
NC license 2007-01762
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Unc Hospitals Chapel Hill, NC
- Rex Hospital Raleigh, NC
Medical groups
- University of North Carolina at Chapel Hill (2,052 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 372
- Services billed
- 1,415
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Antibody evaluation, each additional single antibody stain procedure | 344 | 80 |
| Destruction of precancer skin growth, 2-14 growths | 283 | 58 |
| Established patient office or other outpatient visit, 30-39 minutes | 249 | 147 |
| Established patient office or other outpatient visit, 20-29 minutes | 150 | 131 |
| Antibody evaluation, initial single antibody stain procedure | 104 | 88 |
| Destruction of precancer skin growth, 1 growth | 81 | 76 |
| Biopsy of related skin growth, first growth | 58 | 53 |
| Destruction of skin growth, 1-14 growths | 53 | 48 |
| New patient office or other outpatient visit, 45-59 minutes | 33 | 33 |
| New patient office or other outpatient visit, 30-44 minutes | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Methotrexate (methotrexate sodium) Other prescribers in Chapel Hill, NC | 80 |
| Prednisone Other prescribers in Chapel Hill, NC | 61 |
| Hydroxychloroquine Sulfate Other prescribers in Chapel Hill, NC | 51 |
| Metronidazole Other prescribers in Chapel Hill, NC | 35 |
| Clobetasol Propionate Other prescribers in Chapel Hill, NC | 32 |
| Dapsone | 31 |
| Mycophenolate Mofetil Other prescribers in Chapel Hill, NC | 30 |
| Fluconazole Other prescribers in Chapel Hill, NC | 18 |
| Dupixent Pen (dupilumab) Other prescribers in Chapel Hill, NC | 17 |
| Clotrimazole Other prescribers in Chapel Hill, NC | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 44 payments worth $48,163 in total to this clinician.
| Regeneron Pharmaceuticals, Inc. | $31,105 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $14,166 |
| Genzyme Corporation | $2,703 |
| Journey Medical Corporation | $85.13 |
| Leo Pharma Inc. | $70.60 |
| Takeda Pharmaceuticals U.S.A., Inc. | $31.17 |
| Pfizer Inc. | $3.09 |
| Consulting Fee | $29,697 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $15,912 |
| Travel and Lodging | $1,685 |
| Food and Beverage | $869 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Jul 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $10,675 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $7,163 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $5,124 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $5,124 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $3,820 |
| Genzyme Corporation Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $2,604 |
| Regeneron Healthcare Solutions, Inc. Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,135 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,910 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,708 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,708 |
All 27 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $7,163 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $3,820 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,910 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $716 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $478 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $239 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to CHICAGO, IL · in-kind | $42.00 |
| Regeneron Pharmaceuticals, Inc. Oct 17, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to CHICAGO, IL · in-kind | $186 |
| Regeneron Pharmaceuticals, Inc. Oct 17, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to CHICAGO, IL · in-kind | $186 |
| Regeneron Pharmaceuticals, Inc. Oct 13, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to CHICAGO, IL · in-kind | $292 |
| Regeneron Pharmaceuticals, Inc. Sep 12, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to CHICAGO, IL · in-kind | $200 |
| Regeneron Pharmaceuticals, Inc. Sep 12, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to CHICAGO, IL · in-kind | $35.25 |
| Regeneron Healthcare Solutions, Inc. Sep 5, 2025 | Travel and Lodging travel to PITTSBURGH, PA · in-kind | $106 |
| Regeneron Healthcare Solutions, Inc. Sep 5, 2025 | Travel and Lodging travel to PITTSBURGH, PA · in-kind | $21.00 |
| Regeneron Healthcare Solutions, Inc. Jul 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $10,675 |
| Regeneron Healthcare Solutions, Inc. Jul 10, 2025 | Travel and Lodging travel to PITTSBURGH, PA · in-kind | $295 |
| Regeneron Healthcare Solutions, Inc. Jun 11, 2025 | Travel and Lodging travel to PITTSBURGH, PA · in-kind | $322 |
| Genzyme Corporation Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $2,604 |
| Regeneron Healthcare Solutions, Inc. Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,135 |
| Regeneron Healthcare Solutions, Inc. Apr 4, 2025 | Compensation for services other than consulting (speaking, faculty) | $498 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $5,124 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $5,124 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,708 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,708 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $854 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $427 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $427 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $98,415 in research payments for these studies, mostly to the institutions running them.
- A phase 3 external and synthetic placebocontrolled randomized study with doseup for nonresponders to investigate safety and efficacy of ritlecitinib 50 mg and 100 mg once daily in adult and adolescent participants 12 …
Pfizer Inc. - A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Contro…
Novartis Pharmaceuticals Corporation - A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
Regeneron Pharmaceuticals, Inc. · Completed · NCT04206553
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.